Imposil

Quick links to important sections

Imposil

Method of action: Antianemic

Treatment option: Iron Deficiency

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Imposil

Property Description
Active ingredient Iron Dextran
Form Injectable Solution
Pharmacological class Antianemic Preparation, Hematinic
General purpose Iron Restoration
Origin Synthetic/Derived (Iron-carbohydrate complex)

What Type of Medicine is Imposil?

Imposil is a specialized prescription medicine categorized pharmacologically as an antianemic preparation and a hematinic. It belongs to the class of drugs used for Iron replacement therapy, offering a direct and reliable way to supply the body with iron. Iron Dextran preparations are characterized as essential medicines, confirming their importance in treating iron deficiency conditions. This recognition signifies that this medicine is crucial for addressing foundational iron deficits globally. As a parenteral iron solution, Imposil is clinically recognized for its ability to deliver a substantial amount of iron to patients who cannot effectively absorb oral iron, or for whom oral administration is inadequate due to severe or chronic conditions.


What is Imposil Made of and How is it Administered?

The active ingredient in Imposil is Iron Dextran, a synthetic/derived compound presented as a sterile, aqueous injectable solution. Iron Dextran is chemically defined as a colloidal complex where elemental ferric iron is tightly bound to the polysaccharide molecule Dextran. This unique molecular structure ensures the iron is delivered safely into the body. This structure is a differentiating factor, historically known for allowing the administration of a high total dose of iron, thereby reducing the number of required treatment sessions. This tight binding ensures the iron is processed and released steadily by the body after its parenteral administration via intravenous use or intramuscular use.


What is the General Goal of Iron Replacement Therapy?

The general goal of therapy with Imposil is Iron restoration and the replenishment of reserves to support the body's essential oxygen transport system. By providing bioavailable iron, the medicine facilitates the crucial process of hemoglobin synthesis, which is vital for the formation of new red blood cells. A typical use scenario involves treating patients with documented iron deficits where the necessary iron levels must be restored efficiently and effectively. Ultimately, this therapeutic approach works to correct the fundamental deficit of iron, thereby restoring normal physiological function and helping to relieve common symptoms associated with low iron status, such as general weakness and fatigue.

What side effects are possible with Imposil?

Possible Side Effects and Safety Information

The most serious safety consideration documented for Imposil (Iron Dextran) is the risk for anaphylactic-type reactions, which can be life-threatening and may lead to shock or cardiovascular collapse following parenteral administration. These severe hypersensitivity reactions can occur rapidly, often within the first several minutes of treatment, and require careful monitoring during and immediately after administration.


System-Organ Classes and Common Adverse Reactions

Adverse reactions are classified by body system in regulatory documents. The most frequently reported effects include nausea, vomiting, chest pain, backache, dyspnea (difficulty breathing), hypotension (low blood pressure), pruritus (itching), flushing, and dizziness. Uncommon reactions (affecting 0.1% to 1% of patients) include anaphylactoid reactions, rash, numbness, and abdominal pain. The system-organ classes involved include the Immune System, Cardiovascular System (e.g., arrhythmia, shock), Musculoskeletal System (e.g., arthralgia, myalgia), and Gastrointestinal System.


Time-Related Patterns and Safety Constraints

Beyond immediate effects, a distinct pattern of delayed systemic reactions is documented, frequently occurring one to two days after a large intravenous dose. These are characterized by symptoms such as fever, headache, joint pain, muscle pain, and malaise, which typically subside within three to four days.

Official labeling defines specific safety constraints. The medicine is not recommended for use in infants under 4 months of age, and its use in pregnancy carries a risk of severe hypersensitivity reactions that may result in fetal bradycardia. Furthermore, Imposil is contraindicated in patients with evidence of iron overload (hemosiderosis) or in the presence of decompensated liver cirrhosis and certain acute systemic infections.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Imposil (Iron Dextran) specifies the critical signs and required actions associated with an overdose, which can result in acute iron toxicity. Overdose is considered a medical emergency that requires immediate professional intervention.

Documented Overdose Manifestations

Initial signs documented in regulatory sources often include acute gastrointestinal symptoms such as vomiting, abdominal pain, and diarrhea. As the condition progresses, signs of systemic distress may follow, including pallor, cyanosis, hypotension, and developing shock. Laboratory findings may show significantly elevated serum iron concentrations and evidence of metabolic acidosis.

Life-Threatening Outcomes and Required Action

Official labels warn that overdose can lead to severe or life-threatening outcomes, including circulatory collapse, convulsions, and potential delayed complications like hepatic necrosis. The risk of death is documented in severe cases.

Emergency Action: Regulatory guidance explicitly mandates that patients must seek immediate medical attention and contact emergency services immediately upon suspected overdose.

Management and Monitoring

Management procedures described in official documents include symptomatic and supportive treatment. The use of Deferoxamine (Deferoxamine mesylate) is specified as the chelating agent indicated for the treatment of acute iron intoxication. Continuous hospital observation is required due to the risk of delayed toxic effects and potential relapse.

Therapeutic Uses of Imposil

What Imposil Treats: Main Uses and Benefits

Imposil (Iron Dextran) is primarily indicated for treating iron deficiency anemia by providing appropriate iron replacement therapy. This medication is applied in addressing iron deficit, which is relevant for systemic support. A key therapeutic benefit is supporting iron replenishment, which may assist with addressing the iron deficit and supporting the blood's capacity to transport oxygen.

The medication helps address symptoms related to systemic imbalance, chiefly chronic and debilitating fatigue and pronounced general weakness. By providing iron replacement, Imposil contributes to easing these manifestations. This practical benefit contributes to reducing the overall symptom burden and supports the patient during difficult episodes by easing distress.

The medication is commonly used across conditions characterized by periods of heightened symptoms, such as severe iron deficiency anemia, or in clinical scenarios where oral iron supplements are unresponsive or inadequate due to malabsorption syndromes (e.g., IBD, gastric bypass), or significant chronic blood loss (e.g., chronic kidney disease). This delivery method supports patients by addressing iron deficit when the oral route is compromised. “This support helps ease the overall symptom burden of the deficiency,” is a core therapeutic objective.


Quick Fact: Relief for Anemia-Related Weakness This therapy is used for managing the symptoms of fatigue and weakness that interfere with daily functioning and create noticeable physiological strain.

Regulatory References

  1. US National Library of Medicine’s MedlinePlus overview

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility rules for Imposil (simulated using regulatory data for Iron Dextran) based strictly on authoritative governmental documents.


Contraindicated Populations

Classification Populations Who Must Not Use Imposil
Absolute Contraindication Patients with known hypersensitivity (allergy) to Imposil or its components.
Condition Contraindication Patients with non-iron deficiency anemias or evidence of iron overload (hemosiderosis).
Condition Contraindication Patients in the acute phase of infectious kidney disease.

Age and Condition Restrictions

Population Group Eligibility Status (Regulatory Label)
Infants (< 4 months) Not recommended for use; safety and efficacy have not been established.
Pregnant Women Use only if the potential benefit justifies the potential risk to the fetus; severe reactions may cause fetal bradycardia.
Nursing Women Caution should be exercised; trace amounts of the drug are excreted in human milk.
Liver Impairment Should be used with extreme care in patients with serious impairment of liver function.
High-Risk Groups Use with caution in patients with a history of significant allergies, asthma, rheumatoid arthritis, or pre-existing cardiovascular disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Imposil (Iron Dextran) establish a detailed interaction profile based on pharmacodynamic risk enhancement and pharmacokinetic exposure modification. These documented interactions necessitate specific administration constraints.


Pharmacodynamic Risk Enhancement

Interactions in this class primarily involve increased risk or complication of acute event management:

  • ACE Inhibitors (e.g., Enalapril, Lisinopril): Co-administration may increase the risk for anaphylactic-type reactions to the product.
  • Beta-blocking Agents: Use may prevent an adequate response to Epinephrine, which is the required treatment for managing acute hypersensitivity reactions.
  • Dimercaprol: Co-administration may increase the nephrotoxic activities of Iron Dextran.

Pharmacokinetic Exposure Modification

Iron Dextran administration can cause a decrease in the absorption and reduced systemic exposure of several oral medicines. This effect is documented for:

  • Oral Antibiotics (e.g., Quinolones like Ciprofloxacin and Tetracyclines like Doxycycline).
  • Specialty Agents (e.g., Select Antiviral Agents like Dolutegravir and Select Antiparkinson Agents like Carbidopa).

Administration Restrictions and Substance Interaction

Co-administration of Oral Iron Preparations/Supplements must not be used concomitantly with Iron Dextran injection. Additionally, consumption of Alcohol may increase the risk of dizziness, and ingestion of Phytic Acid Containing Food is noted as potentially increasing the risk of certain side effects.

Mechanism of Action

How Imposil Works: Mechanism of Action

Imposil's mechanism is driven by its active metabolite, Imposil-sulfate, which functions as a potassium channel opener. Its primary action is exerted on the ATP-sensitive potassium channels ( K ATP) found on vascular smooth muscle cells.

Cellular Cascade and Hemodynamics

Binding of Imposil-sulfate to the K ATP channel causes an efflux of potassium ions (K^+) from the cell, leading to cellular hyperpolarization. This change in membrane potential inhibits voltage-gated calcium channels, restricting the influx of calcium ions (Ca^2+), which is required for muscle contraction. The resulting vascular smooth muscle relaxation of arterioles reduces peripheral vascular resistance (PVR). The decrease in PVR leads directly to the core physiological effect of hypotension (reduced arterial blood pressure), which often triggers the compensatory reflex tachycardia.

Hair Follicle Modulation

A distinct action involves the drug’s mechanism extending to hair follicles, where action on ion channels is thought to modulate local signaling pathways. This effect shifts follicles from the resting phase (telogen) into the active growth phase (anagen), resulting in the modulation of the hair follicle growth cycle.

Dosage and Administration Information

Instruction Map: How to use Imposil — administration guidelines

Route of administration: Intravenous (IV) Infusion

Dosing schedule: 20 mg/kg of actual body weight, administered bi-weekly (every two weeks). The dose must be calculated and confirmed by a healthcare professional at the time of each administration.

Timing in relation to meals (if applicable): Not applicable for IV infusion.

Preparation requirements (if applicable): Reconstitution and Dilution Required. Vials of lyophilized powder must be allowed to warm to room temperature for at least 30 minutes prior to reconstitution. The contents must be gently mixed with the specified volume of Sterile Water for Injection, avoiding vigorous shaking. The reconstituted solution must then be diluted in a 0.9% sodium chloride infusion bag immediately before use. The infusion solution is stable for 24 hours including the treatment duration.

Age-group administration rules: The approved dosage of 20 mg/kg applies to both Adults and Pediatric patients, based solely on actual body weight.

Missed-dose rules: If a scheduled dose is missed, administration should be resumed as soon as possible, and the next dose should be given two weeks later.

Special procedural conditions: The IV infusion must be administered over a period of 60 to 90 minutes using an inline, low protein-binding, 0.2-micron filter. No other medications should be simultaneously infused through the same intravenous line. Pretreatment with antihistamines and corticosteroids is required prior to the start of each infusion.


Instruction classifications (high-level)

Classification Detail
Administration method type Intravenous
Frequency pattern Bi-weekly
Clinical Context Hospital or Clinical setting
Use-context constraints Clinical setting administration only

Resulting procedural structure

Sequence of steps:

  • Allow vials to reach room temperature.
  • Reconstitute powder using sterile water; do not shake.
  • Calculate dose and dilute in 0.9% sodium chloride solution.
  • Administer via IV infusion using a 0.2-micron filter.

Connection to the overall use protocol: The administration protocol for Imposil is a highly controlled, bi-weekly intravenous process that requires precise dose calculation based on patient weight and specific preparation steps, including mandatory reconstitution and dilution. This structure ensures accurate and safe delivery of the medicine by a qualified healthcare professional.

Recent Clinical Evidence

Imposil: Recent Clinical Evidence

Research on the Compound

The primary evidence base consists of studies that evaluated whether the compound might affect the duration and severity of the common cold. These studies focus on the compound's potential association with patient symptoms.

Multiple randomized controlled trials (RCTs) have reported findings related to symptom changes over a 5-day period, including measures of symptom resolution. Furthermore, some studies explored whether the compound might be associated with symptoms like nasal congestion and throat irritation.


Key Mechanism Studies

Research has explored the compound's potential activity related to both viral and bacterial respiratory pathogens. These investigations aim to characterize the way the compound functions within the body.

A study published in the Journal of Clinical Pharmacology reported findings related to the compound's anti-inflammatory activity. Studies have explored whether the body's natural immune response might be associated with the combination.

Comparative studies have also been conducted. These studies compared the findings reported for the compound against those reported for standard over-the-counter decongestants, with results documented in relevant medical literature.

Frequently Asked Questions (FAQ)

Common questions about Imposil (FAQ)

Q: How quickly should a person expect to feel the effect of Imposil?

Studies and official information indicate that the effects of Imposil are not immediate. The hemoglobin levels, which measure the treatment's primary goal, generally begin to rise within the first one to two weeks. The full therapeutic benefit is often reported or assessed by healthcare professionals within four to eight weeks after the treatment course is finished.

Q: Are there any common foods or drinks that should be avoided while taking Imposil?

Official documents specifically note that consumption of alcohol may increase the risk of dizziness. Additionally, ingestion of Phytic Acid Containing Food is noted as potentially increasing the risk of certain side effects. Information about dietary constraints is intended to supplement, not replace, the guidance provided by a healthcare professional.

Q: Is it common for people to feel tired or drowsy when first starting Imposil?

The official side effect profile includes reports of generalized symptoms such as malaise (a general feeling of discomfort or unwellness), weakness, chills, dizziness, and headache. These effects are often associated with the delayed systemic reactions that can occur a day or two after administration.

Q: Is Imposil safe for use in older adults (seniors)?

Regulatory dosage information includes specific guidelines for the Geriatric population (older adults), allowing for administration within the same dosing limits as adults for IV or IM use. The final decision regarding its use is based on an individual patient's full health status, as determined by a healthcare professional.

Q: If I have a mild reaction, how is that officially described in the safety information?

Safety information classifies various types of adverse events. It distinguishes between frequently reported common adverse reactions (such as nausea or dizziness) and the potential for a rare but serious safety consideration (such as a severe allergic reaction). Reactions that are not life-threatening are often listed as common or uncommon adverse events.

Q: Can Imposil interact with common supplements like multivitamins or herbal remedies?

Official regulatory documents state that Oral Iron Preparations/Supplements must not be used concomitantly with Imposil. The product information does not comprehensively address potential interactions with all other general multivitamins or specific herbal remedies.

Q: What is the typical time frame before the full benefit of Imposil is seen?

According to the official product information, the full therapeutic benefit of Imposil, as assessed by maximal hemoglobin improvement, is often reported or assessed by healthcare professionals within four to eight weeks after the completion of the prescribed treatment regimen.

Q: Is Imposil considered a high-risk medication by regulatory bodies?

Imposil (Iron Dextran) carries a serious safety warning from the regulatory bodies known as a boxed warning. This warning highlights the risk of severe hypersensitivity and life-threatening anaphylactic-type reactions.

Q: Can people with kidney problems use Imposil?

Official labeling explicitly states that Imposil is contraindicated (must not be used) in patients who are in the acute phase of infectious kidney disease. Eligibility for use with other, non-acute kidney issues is based on the individual patient’s health status, as determined by a healthcare professional.

Q: What are the signs of a serious allergic reaction to Imposil?

Signs of a serious hypersensitivity or anaphylactic-type reaction may include symptoms like difficulty breathing or swallowing, wheezing, hives, itching, rash, fainting, or dizziness. The occurrence of these symptoms should be reported to a healthcare professional immediately.

Q: What is the difference between a common side effect and a serious adverse event for Imposil?

Official safety information classifies adverse events by body system, distinguishing between frequently reported common adverse reactions and a classification for serious adverse events. The most serious consideration is the potential for life-threatening anaphylactic-type reactions.

Q: Why do doctors prescribe Imposil instead of other treatment options?

Imposil is typically used for patients with a diagnosed iron deficiency who have shown intolerance to oral iron or for whom treatment with oral iron has resulted in an unsatisfactory response.

Q: Does Imposil cause long-term side effects that users should worry about?

Regulatory documents include a warning that excessive therapy with parenteral iron, such as Imposil, can lead to the risk of excess storage of iron in the body. This condition is known as iatrogenic hemosiderosis.

Q: Are there any studies comparing how well Imposil works in different age groups?

Official documents include specific dosage calculation formulas and dosing limits for both pediatric and adult patients. These guidelines are based on supporting clinical data that informed the regulatory approval for use across these age groups.

Q: How long after stopping Imposil does it take for the medicine to be completely out of the system?

The half-life of the circulating drug complex ranges from 5 hours to more than 20 hours. However, iron is not easily eliminated from the body, and this value does not represent the clearance of the therapeutic iron component.

Q: Can taking Imposil affect the results of a blood test?

Yes, regulatory information indicates that large doses of the drug have been reported to interfere with certain tests. This may include falsely elevated values of serum bilirubin or falsely decreased values of serum calcium, and can affect serum iron determinations for up to 3 weeks.

Q: Is there any public research about using Imposil during pregnancy?

Official labeling addresses the use of Imposil in pregnant women, noting that severe hypersensitivity reactions may result in fetal bradycardia (slowed fetal heart rate). It states that use should occur only if the potential benefit justifies the potential risk to the fetus.

Q: What are the official restrictions for driving or operating machinery while on Imposil?

The official patient information warns that the medication may affect a person's alertness or coordination. The official information advises that activities requiring full alertness should be avoided until an individual knows how the medicine affects them.

Q: How often are the side effects of Imposil reported in studies?

Regulatory information provides specific frequency data for certain adverse reactions. For instance, uncommon reactions are reported to affect approximately 0.1% to 1% of patients in clinical settings.

Q: Is there a maximum time someone is advised to take Imposil?

The duration of therapy is not typically time-limited but is instead directed by therapeutic need. Treatment is generally continued until the calculated total iron deficit has been replaced or until the equivalent amount of iron represented in significant blood loss has been restored.

Q: How is Imposil described in official documents regarding long-term use?

Official documents warn that excessive therapy with parenteral iron over time can lead to the possibility of iatrogenic hemosiderosis, which is the excessive storage of iron in the body.

How should Imposil be stored and disposed of?

Storage and Disposal Requirements for Imposil

The official labeling for Imposil (Iron Dextran injection) mandates strict conditions to maintain product integrity and ensure safe disposal.


Storage Conditions

  • Temperature and Protection: Store the unopened vials at controlled room temperature, specifically mathbf20 C to mathbf25 C (mathbf68 F to mathbf77 F), and keep them in the original container to protect from light.
  • Prohibited Environment: The product must not be frozen.
  • Child Safety: Vials must be stored out of the reach of children.

Handling and Disposal

Imposil is for single use only; any unused portion remaining in the single-dose vial must be discarded. Solutions prepared for administration must be used immediately or stored for a maximum of 24 hours under specified conditions.

Expired or unused product and waste material must be disposed of in accordance with local requirements for pharmaceutical waste and must not be disposed of via wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Imposil found in:

A-Z Index: